SEC Form 3 · accession 0001123292-18-001125
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. McElhaugh
Officer — Chief Business Officer
Period of report
Dec 11, 2018
Accepted (ET)
Dec 21, 2018 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | holding | — | — | — | 1,387,457 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.15 | holding | — | — | — | — | Mar 24, 2027 | Common Shares | 25,000 | — | D |
| Employee Stock Option (Right to Buy)F2 | $5.20 | holding | — | — | — | — | Apr 16, 2028 | Common Shares | 41,268 | — | D |
Explanation of responses
- F1The option will vest and become exercisable in three equal annual installments with the first annual installment occurring on March 24, 2018.
- F2The option will vest and become exercisable in three equal annual installments with the first annual installment occurring on April 16, 2019.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney